Managers’ transactions

    Managers’ transactions 

October 14,2024
Announcement no. 27

Managers’ transactions 

Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in Pharma Equity Group A/S made by persons discharging managerial responsibilities in Pharma Equity Group and/or persons closely related with them.  

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name	Christian Vinding Thomsen
2. Reason for the notification
a) Position/status	Chairman of the board of directors
b) Initial notification/amendment	Initial notification
3. Details of the issuer
a) Name	Pharma Equity Group A/S
b) LEI	2138008SUI4D917FKN20
c) Trade name	PEG
4. Details of the transaction(s)
a) Description of the financial instrument, type   of instrument and Identification code	Shares, ISIN code DK0061155009
b) Nature of the transaction	Subscription by conversion of debt
c) Price(s) and volume(s)	Price: DKK 0.25, Volume: 2,139.812
d) Aggregated information  - Aggregated volume  - Aggregated price	Volume: 2,139.812 Price: DKK 534,953
e) Date of the transaction	10-10-2024, 09:00 CEST
f) Place of the transaction	Nasdaq Copenhagen A/S

For further information, please contact: 

Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: [phone] Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: [phone]

About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects. The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

Attachment

• 2024 10 14 Announcement no 27